Top

Current Neurology and Neuroscience Reports

Published in:

01-10-2012 | Demyelinating Disorders (DN Bourdette and V Yadav, Section Editors)

Modifiable Comorbidities and Disability in Multiple Sclerosis

Authors: Shannon Overs, Christina M. Hughes, Jodie K. Haselkorn, Aaron P. Turner

Published in: Current Neurology and Neuroscience Reports | Issue 5/2012

Abstract

Multiple sclerosis is a common neurological disease that results in disability in early adulthood that may progress through a relatively normal lifespan. Other comorbid health conditions can increase the likelihood of progression of MS and independently contribute to limitations in activities and social participation. We examine common modifiable health conditions and behaviors, including hypertension, obesity, diabetes mellitus, alcohol, and smoking to determine their impacts on MS and disability. Appropriate identification and treatment can improve health status, diminish disability, and improve quality of life.

Dean G. How many people in the world have multiple sclerosis? Neuroepidemiology. 1994;13:1–7.PubMedCrossRef

Weinshenker BG. Epidemiology of multiple sclerosis. Neurol Clin. 1996;14:291–308.PubMedCrossRef

Ebers GC. Natural history of multiple sclerosis. J Neurol Neurosurg Psychiatry. 2001;71 Suppl 2:16–9.

Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain. 1989;112(Pt 1):133–46.PubMedCrossRef

Marrie RA, Horwitz RI, Cutter G, et al. Association between comorbidity and clinical characteristics of MS. Acta Neurol Scand. 2011;124:135–41.PubMedCrossRef

• Marrie RA, Horwitz RI. Emerging effects of comorbidities on multiple sclerosis. Lancet Neurol. 2010;9:820–8. The authors broadly identify which comorbidities occur in patients with MS, which are most common, and whether they occur with greater or less frequency than in the general population. They found that an increasing amount of evidence suggests that comorbidities and lifestyle factors might affect the diagnostic delay between MS onset and diagnosis, the clinical phenotype of MS, disability progression, health-related quality of life, and treatment decisions. Further research is needed to answer many questions about comorbidities associated with MS, including the best way to measure and analyze comorbidities to understand these associations. PubMedCrossRef

• Marrie RA, Rudick R, Horwitz R, et al. Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. Neurology. 2010;74:1041–7. The authors discussed the results of the October 2006 NARCOMS Registry survey on comorbidities, including the year of diagnosis. They linked this information to demographic and clinical information related to MS disability progression. They demonstrated that the presence of vascular comorbidities led to more rapid disability progression and the need for assistive walking devices. PubMedCrossRef

Obisesan TO. Hypertension and cognitive function. Clin Geriatr Med. 2009;25:259–88.PubMedCrossRef

Tall MW, Chertow GM, Marsden PA, et al., editors. Brenner & Rector's the kidney. Philadelphia: Saunders/Elsevier; 2011.

10.

Centers for Disease Control and Prevention. Prevalence of disability and associated health conditions, US 1991–1992. MMWR Morb Mortal Wkly Rep. 1994;40:730–9.

11.

Rosano C, Longstreth Jr WT, Boudreau R, et al. High blood pressure accelerates gait slowing in well-functioning older adults over 18-years of follow-up. J Am Geriatr Soc. 2011;59:390–7.PubMedCrossRef

12.

Hajjar I, Quach L, Yang F, et al. Hypertension, white matter hyperintensities, and concurrent impairments in mobility, cognition, and mood: the Cardiovascular Health Study. Circulation. 2011;123:858–65.PubMedCrossRef

13.

Kang JH, Chen YH, Lin HC. Comorbidities amongst patients with multiple sclerosis: a population-based controlled study. Eur J Neurol. 2010;17:1215–9.PubMedCrossRef

14.

Marrie RA, Cutter G, Tyry T. Substantial adverse association of visual and vascular comorbidities on visual disability in multiple sclerosis. Mult Scler. 2011;17:1464–71.PubMedCrossRef

15.

Dallmeijer AJ, Beckerman H, de Groot V, et al. Long-term effect of comorbidity on the course of physical functioning in patients after stroke and with multiple sclerosis. J Rehabil Med. 2009;41:322–6.PubMedCrossRef

16.

Ranadive SM, Yan H, Weikert M, et al. Vascular dysfunction and physical activity in multiple sclerosis. Med Sci Sports Exerc. 2012;44:238–43.PubMedCrossRef

17.

Fjeldstad AS, McDaniel J, Witman MA, et al. Vascular function and multiple sclerosis. J Neurol. 2011;258:2036–42.PubMedCrossRef

18.

Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet. 2011;378:31–40.PubMedCrossRef

19.

Centers for Disease Control and Prevention. general information and national estimates on diabetes in the United States, 2007: U.S. Department of Health and Human Services; 2008.

20.

De Souza CT, Araujo EP, Bordin S, et al. Consumption of a fat-rich diet activates a proinflammatory response and induces insulin resistance in the hypothalamus. Endocrinology. 2005;146:4192–9.PubMedCrossRef

21.

Barcellos LF, Kamdar BB, Ramsay PP, et al. Clustering of autoimmune diseases in families with a high-risk for multiple sclerosis: a descriptive study. Lancet Neurol. 2006;5:924–31.PubMedCrossRef

22.

Dorman JS, Steenkiste AR, Burke JP, Songini M. Type 1 diabetes and multiple sclerosis: together at last. Diabetes Care. 2003;26:3192–3.PubMedCrossRef

23.

Watson GS, Craft S. Insulin resistance, inflammation, and cognition in Alzheimer's disease: lessons for multiple sclerosis. J Neurol Sci. 2006;245:21–33.PubMedCrossRef

24.

Resnick HE, Stansberry KB, Harris TB, et al. Diabetes, peripheral neuropathy, and old age disability. Muscle Nerve. 2002;25:43–50.PubMedCrossRef

25.

Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999–2008. JAMA. 2010;303:235–41.PubMedCrossRef

26.

Maffei M, Halaas J, Ravussin E, et al. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med. 1995;1:1155–61.PubMedCrossRef

27.

Matarese G, Carrieri PB, La Cava A, et al. Leptin increase in multiple sclerosis associates with reduced number of CD4(+)CD25+ regulatory T cells. Proc Natl Acad Sci U S A. 2005;102:5150–5.PubMedCrossRef

28.

Mohamed-Ali V, Goodrick S, Rawesh A, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab. 1997;82:4196–200.PubMedCrossRef

29.

De Rosa V, Procaccini C, Cali G, et al. A key role of leptin in the control of regulatory T cell proliferation. Immunity. 2007;26:241–55.PubMedCrossRef

30.

Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4 + CD25+ T cell-mediated suppression by dendritic cells. Science. 2003;299:1033–6.PubMedCrossRef

31.

Munger KL, Chitnis T, Ascherio A. Body size and risk of MS in two cohorts of US women. Neurology. 2009;73:1543–50.PubMedCrossRef

32.

Khurana SR, Bamer AM, Turner AP, et al. The prevalence of overweight and obesity in veterans with multiple sclerosis. Am J Phys Med Rehabil. 2009;88:83–91.PubMedCrossRef

33.

Malnick SD, Knobler H. The medical complications of obesity. QJM. 2006;99:565–79.PubMedCrossRef

34.

Bombardier CH, Blake KD, Ehde DM, et al. Alcohol and drug abuse among persons with multiple sclerosis. Mult Scler. 2004;10:35–40.PubMedCrossRef

35.

Marrie R, Horwitz R, Cutter G, et al. High frequency of adverse health behaviors in multiple sclerosis. Mult Scler. 2009;15:105–13.PubMedCrossRef

36.

Quesnel S, Feinstein A. Multiple sclerosis and alcohol: a study of problem drinking. Mult Scler. 2004;10:197–201.PubMedCrossRef

37.

Turner AP, Hawkins EJ, Haselkorn JK, Kivlahan DR. Alcohol misuse and multiple sclerosis. Arch Phys Med Rehabil. 2009;90:842–8.PubMedCrossRef

38.

Nortvedt MW, Riise T, Maeland JG. Multiple sclerosis and lifestyle factors: the Hordaland Health Study. Neurol Sci. 2005;26:334–9.PubMedCrossRef

39.

National Institute on Alcohol Abuse and Alcoholism. State of the science report on the effects of moderate drinking: US Department of Health and Human Services; 2003.

40.

Bradley KA, Maynard C, Kivlahan DR, et al. The relationship between alcohol screening questionnaires and mortality among male veteran outpatients. J Stud Alcohol. 2001;62:826–33.PubMed

41.

Rehm J, Greenfield TK, Rogers JD. Average volume of alcohol consumption, patterns of drinking, and all-cause mortality: results from the US National Alcohol Survey. Am J Epidemiol. 2001;153:64–71.PubMedCrossRef

42.

Thun MJ, Peto R, Lopez AD, et al. Alcohol consumption and mortality among middle-aged and elderly U.S. adults. N Engl J Med. 1997;337:1705–14.PubMedCrossRef

43.

Feinstein A. An examination of suicidal intent in patients with multiple sclerosis. Neurology. 2002;59:674–8.PubMedCrossRef

44.

Goodin DS. Survey of multiple sclerosis in northern California. Northern California MS Study Group. Mult Scler. 1999;5:78–88.PubMed

45.

D'Hooghe MB, Nagels G, Bissay V, De Keyser J. Modifiable factors influencing relapses and disability in multiple sclerosis. Mult Scler. 2010;16:773–85.PubMedCrossRef

46.

D'Hooghe MB, Haentjens P, Nagels G, De Keyser J. Alcohol, coffee, fish, smoking and disease progression in multiple sclerosis. Eur J Neurol. 2012;19:616–24.PubMedCrossRef

47.

Borzecki AM, Lee A, Kalman D, Kazis LE. Do poor health behaviors affect health-related quality of life and healthcare utilization among veterans? The Veterans Health Study. J Ambul Care Manage. 2005;28:141–56.PubMed

48.

Davies SJ, Pandit SA, Feeney A, et al. Is there cognitive impairment in clinically 'healthy' abstinent alcohol dependence? Alcohol Alcohol. 2005;40:498–503.PubMed

49.

Parsons OA, Nixon SJ. Cognitive functioning in sober social drinkers: a review of the research since 1986. J Stud Alcohol. 1998;59:180–90.PubMed

50.

Vik PW, Cellucci T, Jarchow A, Hedt J. Cognitive impairment in substance abuse. Psychiatr Clin North Am. 2004;27:97–109. ix.PubMedCrossRef

51.

Mangold S, Laubli T, Krueger H. Effects of a low alcohol dose on static balance, fine motor activity, and mental performance. Neurotoxicol Teratol. 1996;18:547–54.PubMedCrossRef

52.

Schweizer TA, Vogel-Sprott M, Danckert J, et al. Neuropsychological profile of acute alcohol intoxication during ascending and descending blood alcohol concentrations. Neuropsychopharmacology. 2006;31:1301–9.PubMed

53.

Wang MQ, Taylor-Nicholson ME, Airhihenbuwa CO, et al. Psychomotor and visual performance under the time-course effect of alcohol. Percept Mot Skills. 1992;75:1095–106.PubMed

54.

Centers for Disease Control and Prevention. Vital signs: current cigarette smoking among adults aged ≥18 years—United States, 2005–2010. MMWR Morb Mortal Wkly Rep. 2011;60:1207–12.

55.

The health consequences of smoking: a report of the Surgeon General. Washington DC: Dept. of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2004.

56.

Healy BC, Ali EN, Guttmann CR, et al. Smoking and disease progression in multiple sclerosis. Arch Neurol. 2009;66:858–64.PubMedCrossRef

57.

Hedstrom AK, Baarnhielm M, Olsson T, Alfredsson L. Tobacco smoking, but not Swedish snuff use, increases the risk of multiple sclerosis. Neurology. 2009;73:696–701.PubMedCrossRef

58.

Turner AP, Kivlahan DR, Kazis LE, Haselkorn JK. Smoking among veterans with multiple sclerosis: prevalence correlates, quit attempts, and unmet need for services. Arch Phys Med Rehabil. 2007;88:1394–9.PubMedCrossRef

59.

Antonovsky A, Leibowitz U, Smith HA, et al. Epidemiologic study of multiple sclerosis in Israel: I. An overall review of methods and findings. Arch Neurol. 1965;13:183–93.PubMedCrossRef

60.

Villard-Mackintosh L, Vessey MP. Oral contraceptives and reproductive factors in multiple sclerosis incidence. Contraception. 1993;47:161–8.PubMedCrossRef

61.

Thorogood M, Hannaford PC. The influence of oral contraceptives on the risk of multiple sclerosis. Br J Obstet Gynaecol. 1998;105:1296–9.PubMedCrossRef

62.

Hernan MA, Olek MJ, Ascherio A. Cigarette smoking and incidence of multiple sclerosis. Am J Epidemiol. 2001;154:69–74.PubMedCrossRef

63.

Carlens C, Hergens MP, Grunewald J, et al. Smoking, use of moist snuff, and risk of chronic inflammatory diseases. Am J Respir Crit Care Med. 2010;181:1217–22.PubMedCrossRef

64.

Pekmezovic T, Drulovic J, Milenkovic M, et al. Lifestyle factors and multiple sclerosis: a case–control study in Belgrade. Neuroepidemiology. 2006;27:212–6.PubMedCrossRef

65.

Zorzon M, Zivadinov R, Nasuelli D, et al. Risk factors of multiple sclerosis: a case–control study. Neurol Sci. 2003;24:242–7.PubMedCrossRef

66.

Riise T, Nortvedt MW, Ascherio A. Smoking is a risk factor for multiple sclerosis. Neurology. 2003;61:1122–4.PubMedCrossRef

67.

Handel AE, Williamson AJ, Disanto G, et al. Smoking and multiple sclerosis: an updated meta-analysis. PLoS One. 2011;6:e16149.PubMedCrossRef

68.

Hawkes CH. Smoking is a risk factor for multiple sclerosis: a metanalysis. Mult Scler. 2007;13:610–5.PubMedCrossRef

69.

Hedstrom AK, Baarnhielm M, Olsson T, Alfredsson L. Exposure to environmental tobacco smoke is associated with increased risk for multiple sclerosis. Mult Scler. 2011;17:788–93.PubMedCrossRef

70.

Hernan MA, Jick SS, Logroscino G, et al. Cigarette smoking and the progression of multiple sclerosis. Brain. 2005;128:1461–5.PubMedCrossRef

71.

Pittas F, Ponsonby AL, van der Mei IA, et al. Smoking is associated with progressive disease course and increased progression in clinical disability in a prospective cohort of people with multiple sclerosis. J Neurol. 2009;256:577–85.PubMedCrossRef

72.

Sundstrom P, Nystrom L. Smoking worsens the prognosis in multiple sclerosis. Mult Scler. 2008;14:1031–5.PubMedCrossRef

73.

Zivadinov R, Weinstock-Guttman B, Hashmi K, et al. Smoking is associated with increased lesion volumes and brain atrophy in multiple sclerosis. Neurology. 2009;73:504–10.PubMedCrossRef

74.

Koch M, van Harten A, Uyttenboogaart M, De Keyser J. Cigarette smoking and progression in multiple sclerosis. Neurology. 2007;69:1515–20.PubMedCrossRef

75.

van der Mei IA, Simpson Jr S, Stankovich J, Taylor BV. Individual and joint action of environmental factors and risk of MS. Neurol Clin. 2011;29:233–55.PubMedCrossRef

76.

Simon KC, van der Mei IA, Munger KL, et al. Combined effects of smoking, anti-EBNA antibodies, and HLA-DRB1*1501 on multiple sclerosis risk. Neurology. 2010;74:1365–71.PubMedCrossRef

77.

• Hedstrom AK, Sundqvist E, Baarnhielm M, et al. Smoking and two human leukocyte antigen genes interact to increase the risk for multiple sclerosis. Brain. 2011;134:653–64. The authors conducted a population-based case–control study involving incident cases of multiple sclerosis in Sweden. Cases and controls were classified according to their smoking status and human leukocyte antigen DRB1, as well as human leukocyte antigen A genotypes. Subjects with different genotypes and smoking habits were compared with regard to incidence of multiple sclerosis. Smokers, nonsmokers with genetic risk factors, and smokers with genetic risk factors had progressively increasing risks of developing MS. The authors assert that the risk of developing MS associated with human leukocyte antigen genotypes may be strongly influenced by smoking status and that priming of the immune response in the lungs may subsequently lead to multiple sclerosis in genetically susceptible people. PubMedCrossRef

78.

• Aveyard P, Begh R, Parsons A, West R. Brief opportunistic smoking cessation interventions: a systematic review and meta-analysis to compare advice to quit and offer of assistance. Addiction. 2012;107:1066–73. The authors conducted a review of studies examining brief opportunistic physician advice and assistance to stop smoking. Providing advice to quit on medical grounds increased the frequency of quit attempts. Providing support in the form of behavioral counseling or nicotine replacement therapy generated more quit attempts than did advice alone. Intervention increased the likelihood of success from a quit attempt. The authors concluded that physicians may be more effective in promoting attempts to stop smoking by offering assistance to all smokers than by advising smokers to quit and then offering assistance only to those who express an interest in doing so. PubMedCrossRef

79.

Vogt F, Hall S, Marteau TM. General practitioners' and family physicians' negative beliefs and attitudes towards discussing smoking cessation with patients: a systematic review. Addiction. 2005;100:1423–31.PubMedCrossRef

80.

Whitlock EP, Polen MR, Green CA, et al. Behavioral counseling interventions in primary care to reduce risky/harmful alcohol use by adults: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2004;140:557–68.PubMed

81.

Treating tobacco use and dependence. Quick Reference Guide for Clinicians. Washington, DC: US Public Health Service; 2008.

82.

National Institute on Alcohol Abuse and Alcoholism. Helping patients who drink too much: a clinician’s guide. Washington, DC: US Public Health Services; 2005.

83.

Bodenheimer T, Wagner EH, Grumbach K. Improving primary care for patients with chronic illness. JAMA. 2002;288:1775–9.PubMedCrossRef

84.

Wagner EH, Austin BT, Von Korff M. Improving outcomes in chronic illness. Manag Care Q. 1996;4(2):12–25.PubMed

85.

Wagner EH, Austin BT, Von Korff M. Organizing care for patients with chronic illness. Milbank Q. 1996;74:511–44.PubMedCrossRef

86.

Wagner EH. The role of patient care teams in chronic disease management. BMJ. 2000;320:569–72.PubMedCrossRef

87.

Bombardier CH, Cunniffe M, Wadhwani R, et al. The efficacy of telephone counseling for health promotion in people with multiple sclerosis: a randomized controlled trial. Arch Phys Med Rehabil. 2008;89:1849–56.PubMedCrossRef

Title: Modifiable Comorbidities and Disability in Multiple Sclerosis
Authors: Shannon Overs
Christina M. Hughes
Jodie K. Haselkorn
Aaron P. Turner
Publication date: 01-10-2012
Publisher: Current Science Inc.
Published in: Current Neurology and Neuroscience Reports / Issue 5/2012
Print ISSN: 1528-4042
Electronic ISSN: 1534-6293
DOI: https://doi.org/10.1007/s11910-012-0293-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Modifiable Comorbidities and Disability in Multiple Sclerosis

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2012

Therapeutic Hypothermia for Traumatic Brain Injury

Sleep-Disordered Breathing and Cognition in Older Adults

Biomarkers in Traumatic Brain Injury

Insulin: An Emerging Treatment for Alzheimer’s Disease Dementia?

Benign Multiple Sclerosis: Does it exist?

Assessing Dementia in Resource-Poor Regions